Actos, a popular diabetes drug, has been linked to an increased risk of
bladder cancer. If you or someone you care about has been taking this
medication and has been diagnosed with bladder cancer, you should speak
with our team at Sullivan & Brill, LLP. We are knowledge about this
drug and the lawsuits that have been filed against the manufacturer. The
consultation is free and if your case is accepted, you will not be required to pay any fees
or expenses unless a recovery is obtained on your behalf.
Call Sullivan & Brill, LLP for the legal counsel you need and deserve!
Actos, generically known as pioglitazone hydrochloride, is used to treat
Type II diabetes. It is manufactured by Takedia Pharmaceuticals, Inc.
and was put on the market in July of 1999. On September 17, 2010, the
Federal Drug Administration (FDA) issued a safety warning, advising the
public that it was reviewing data from an ongoing study of the association
between Actos and an increased risk of bladder cancer and that the findings
indicate that further study is needed.
In June of 2011, Actos was pulled from the French market after a study
commissioned by the French government confirmed that it was associated
with an increased risk of bladder cancer. In response thereto, in August
of 2011, the FDA ordered Takedia to change the label on Actos to advise
the public of the increased risk of bladder cancer associated with the
drug. Lawsuits have been filed against Takedia Pharmaceuticals alleging
that it knew of this increased risk of bladder cancer, yet it failed to
warn the public, and in fact, affirmatively withheld the fact that some
individuals in a 2005 study of Actos were diagnosed with bladder cancer.
Contact our firm
to discuss your case and learn more about the side effects of Actos.